By: IPP Bureau
Last updated : September 04, 2026 10:16 am
The annual number is projected to rise to approximately 82,252 cases by 2045, underlining the growing need for awareness of treatment options
HCG Cancer Hospitals Mumbai has treated more than 125 prostate cancer patients with Stereotactic Body Radiotherapy (SBRT) using the advanced Versa HD radiation platform. Selected patients have also received highly precise SBRT using CyberKnife, a robotic radiation delivery system.
The treatments have been offered to appropriately selected patients across different prostate cancer risk categories, based on factors including age, cancer stage, risk profile, overall health and individual treatment requirements.
According to the Global Cancer Observatory (GLOBOCAN 2022) of the International Agency for Research on Cancer (IARC–WHO), India recorded an estimated 37,948 new prostate cancer cases in 2022.
The annual number is projected to rise to approximately 82,252 cases by 2045, underlining the growing need for awareness of treatment options.
SBRT delivers highly focused radiation to the tumour while limiting exposure to surrounding healthy tissues. For suitable prostate cancer patients, treatment can be completed in five sessions, generally on an outpatient basis. Unlike surgery, SBRT does not require an incision or removal of the prostate, and patients typically return home after each session.
HCG Cancer Hospital, Colaba, houses what HCG describes as Mumbai's first and only CyberKnife platform. The robotic radiation system combines image guidance with precise radiation delivery and can account for internal movement during treatment, making it particularly useful where accuracy and protection of surrounding organs are critical.
Dr Trinanjan Basu, HOD and Senior Consultant, Radiation Oncology, HCG Cancer Hospitals, Mumbai, said surgery is not the only treatment option for prostate cancer. “For appropriately selected patients, advanced radiation treatment such as SBRT can treat prostate cancer without an incision, surgery or prolonged hospital stay.”
According to HCG, patients treated at its Mumbai centre have included those with intermediate-risk, high-risk and selected metastatic prostate cancer. Most were aged between 60 and 75 years, while around 20 patients were between 75 and 85 years.
Rupesh Choubey, Regional COO, Healthcare Global Enterprises Ltd (Maharashtra & Madhya Pradesh), said HCG's focus is on combining advanced technology with multidisciplinary clinical expertise and precise treatment planning.
Avik Chauhan, Cluster COO, HCG Cancer Hospitals, Mumbai, described the treatment of more than 125 prostate cancer patients with advanced radiation therapy as an important milestone, saying the approach provides patients with less invasive and more convenient treatment options.